The
Asia-Pacific cell and gene therapy manufacturing QC market is expanding rapidly, driven by the rising prevalence of cancers, metabolic, and autoimmune disorders. Increased approvals of cell and gene therapies, along with growing investments and new entrants, are fueling demand for QC solutions. Notably, South Korea has launched a $1.3 billion fund, while Singapore has established key initiatives to boost this sector. These factors are expected to propel market growth from 2024 to 2033.
Asia-Pacific cell and gene therapy Market Overview
The Asia-Pacific cell and gene therapy QC market is driven by stringent quality control regulations, technological advancements, and evolving regulatory frameworks. Industry leaders are leveraging innovative QC solutions and strategic partnerships to seize emerging opportunities. According to BIS Research, the market, valued at $288.9 million in 2024, is projected to reach $1,317.3 million by 2033, growing at a CAGR of 18.36%.
Asia-Pacific cell and gene therapy Market Segmentation
Segmentation 1: based on Offering
• Products
• Services
Segmentation 2: based on Therapy Type
• Cell Therapy
• Gene Therapy
Segmentation 3: based on Process
• Raw Materials Preparation
• Upstream Processing
• Downstream Processing
• Packaging
Segmentation 4: based on Technology
• Polymerase Chain Reaction
• Flow Cytometry
• Limulus Amebocyte Lysate (LAL)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Mass Spectrometry
• Western Blotting
• Next-Generation Sequencing
• Electrophoresis
• Other Technologies
Segmentation 5: based on Application
• Safety Testing
• Potency Testing
• Identity Testing
• Stability and Genetic Fidelity Testing
• Others
Key Market Players
Prominent companies shaping the Asia Pacific Cell and Gene Therapy Manufacturing QC market include:
• Bio-Techne Corporation
• Danaher Corporation (Cytiva)
• F. Hoffmann-La Roche Ltd.
• Lonza
• Miltenyi Biotec B.V. & Co. KG
• Sartorius AG
• Thermo Fisher Scientific Inc.
• WuXi AppTec
• Fujifilm Holdings Corporation
• Merck KGaA
Market Dynamics: Drivers, Challenges, and Opportunities
Market Drivers
The rising regulatory approvals for cell and gene therapies in Asia-Pacific are fueling demand for stringent QC testing. Countries such as Japan, Australia, and South Korea have implemented strict approval processes, necessitating advanced QC measures for safety, efficacy, and consistency. With expanding manufacturing capacities and greater patient access, automated and scalable QC technologies are becoming crucial for meeting industry needs efficiently.
Market Challenges
The high costs of manufacturing and QC pose a major challenge to the widespread adoption of cell and gene therapies. These therapies require complex processes, specialized equipment, skilled personnel, and strict regulatory compliance, driving up expenses. Small and mid-sized biopharma companies face difficulties scaling operations due to the absence of standardized protocols and limited economies of scale, further restricting accessibility.
Market Opportunities
To mitigate cost challenges, industry players are focusing on automation, process optimization, and scalable QC solutions. Collaborations between governments and private stakeholders help to share resources and expertise, easing financial constraints. Additionally, increased regulatory support and funding initiatives are expected to drive the adoption and affordability of these life-saving therapies across the region.
Analyst Perspective
Swati Sood, Principal Analyst at BIS Research, highlights the rapid growth of the Asia-Pacific cell and gene therapy QC market, driven by biopharma innovation, rising R&D investments, and increasing clinical trials. Leading players like Danaher Corporation (Cytiva), Roche, and Thermo Fisher Scientific are advancing QC technologies to meet strict regulations in Japan, Australia, and South Korea. Innovations in automation, AI-driven analytics, and real-time monitoring are improving efficiency, accelerating time-to-market, and solidifying the region’s global presence in cell and gene therapy.
Explore BIS Research’s tailored Go-to-Market Strategy that help businesses explore and enter emerging markets, promising professional guidance to unlock new opportunities.
